According to Zhitong Finance App News, Huakang Biomedical (08622) announced that Huakang Hong Kong, a direct wholly-owned subsidiary of the company, signed a memorandum of understanding with Fujig after the trading session on February 20, 2024. The details include potential sales and distribution cooperation in China (including) selling and distributing the company's biological agents and immediate biomedical testing products on the platforms and channels of Fujig in China. Other than a few provisions (including due diligence, validity and exclusivity, confidentiality, and applicable law and jurisdiction), the MOU is not legally binding.
The directors believe that if the cooperation with pig saving is implemented, it will provide a good opportunity to expand the sales channels of the company's product line in China. The directors believe that this move is in the overall interest of the company and its shareholders.